Dasatinib, Imatinib, Associated With Differing Mutation Patterns in CML

July 10, 2015 | Chronic Myeloid Leukemia, Hematologic Malignancies, Leukemia & Lymphoma Patients with chronic myeloid leukemia (CML) undergoing treatment with dasatinib had a narrower spectrum of mutations in BCR-ABL1 compared to those treated with imatinib, according to a new study, a finding which could aid in selection of second-line treatments. -